Want to see IN:JAGSNPHARM full AI Analyst Report?
JAGSNPHARM Stock Chart & Stats
₹193.50
-₹13.50(-5.18%)
At close: 4:00 PM EST
₹193.50
-₹13.50(-5.18%)
Day’s Range― - ―
52-Week Range₹154.90 - ₹264.65
Previous CloseN/A
Volume94.85K
Average Volume (3M)3.85K
Market Cap
₹15.55B
Enterprise Value₹13.24K
Total Cash (Recent Filing)₹1.06B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)34.8
Beta0.94
Next Earnings
Nov 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.06%
Share Statistics
EPS (TTM)6.80
Shares Outstanding65,929,470
10 Day Avg. Volume3,534
30 Day Avg. Volume3,854
Financial Highlights & Ratios
PEG Ratio-1.29
Price to Book (P/B)4.53
Price to Sales (P/S)4.35
P/FCF Ratio26.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal debt reduces financial risk and interest burden, giving Jagsonpal flexibility to fund product development, sales expansion, and working-capital needs without materially increasing balance-sheet pressure.
Healthy Operating MarginsStrong gross and operating margins indicate the branded-formulations portfolio retains meaningful profitability after production and operating costs, supporting reinvestment and resilience against cost pressure.
Strong Cash ConversionCash generation broadly supports reported profitability, improving the company’s ability to finance operations internally, maintain financial flexibility, and invest in its domestic prescription distribution network.
Bears Say
Earnings VolatilityFalling earnings despite stronger reported revenue suggests inconsistent conversion of growth into profit, making future profitability less predictable and potentially limiting confidence in the durability of recent expansion.
Uneven Margin HistoryHistorical margin inconsistency indicates that product mix, operating costs, or execution can materially affect profitability. Sustaining current margins will therefore remain important for dependable long-term earnings growth.
Choppy Cash-Flow HistoryAlthough recent cash conversion is strong, earlier fluctuations suggest working-capital movements or timing effects can disrupt cash generation. This may create uneven funding capacity for inventory, distribution, and growth initiatives.
Jagsonpal Pharmaceuticals Ltd. News
JAGSNPHARM FAQ
What was Jagsonpal Pharmaceuticals Ltd.’s price range in the past 12 months?
Jagsonpal Pharmaceuticals Ltd. lowest stock price was ₹154.90 and its highest was ₹264.65 in the past 12 months.
What is Jagsonpal Pharmaceuticals Ltd.’s market cap?
Jagsonpal Pharmaceuticals Ltd.’s market cap is ₹15.55B.
When is Jagsonpal Pharmaceuticals Ltd.’s upcoming earnings report date?
Jagsonpal Pharmaceuticals Ltd.’s upcoming earnings report date is Nov 10, 2026 which is in 78 days.
How were Jagsonpal Pharmaceuticals Ltd.’s earnings last quarter?
Jagsonpal Pharmaceuticals Ltd. released its earnings results on Jul 29, 2026. The company reported ₹2.003 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Jagsonpal Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Jagsonpal Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Jagsonpal Pharmaceuticals Ltd. pay dividends?
Jagsonpal Pharmaceuticals Ltd. pays a Annually dividend of ₹4 which represents an annual dividend yield of 1.06%. See more information on Jagsonpal Pharmaceuticals Ltd. dividends here
What is Jagsonpal Pharmaceuticals Ltd.’s EPS estimate?
Jagsonpal Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jagsonpal Pharmaceuticals Ltd. have?
Jagsonpal Pharmaceuticals Ltd. has 65,929,470 shares outstanding.
What happened to Jagsonpal Pharmaceuticals Ltd.’s price movement after its last earnings report?
Jagsonpal Pharmaceuticals Ltd. reported an EPS of ₹2.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.902%.
Which hedge fund is a major shareholder of Jagsonpal Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in IN:JAGSNPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Jagsonpal Pharmaceuticals Ltd.
Jagsonpal Pharmaceuticals Limited, an Indian company founded in 1964 and based in New Delhi, specializes in the development and manufacturing of both bulk active pharmaceutical ingredients and diverse medicinal formulations. Its product portfolio spans three primary therapeutic domains: women's health, pain management and analgesia, and general medical care. Within general medicine, the company offers solutions for allergy control, immune and cellular protection, gastrointestinal and mental wellness, anti-infectives, and products specifically for dental and ear, nose, and throat (ENT) conditions. For women's healthcare, their offerings include pregnancy support and treatments for issues related to dysfunctional uterine bleeding. Furthermore, Jagsonpal provides medications for pain relief and skeletal and joint health. These pharmaceutical items are supplied in common forms like tablets, capsules, and syrups. The company operates as a subsidiary under Aresko Progressive Private Limited.
Technical Analysis
Ind-Swift Laboratories Ltd.
―
Lincoln Pharmaceuticals Ltd
―
Sakar Healthcare Ltd
―
Syncom Formulation (India) Ltd.
―
Venus Remedies Limited
―